KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Other Non-Current Liabilities (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Other Non-Current Liabilities for 16 consecutive years, with $3.9 billion as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Other Non-Current Liabilities fell 9.6% year-over-year to $3.9 billion, compared with a TTM value of $3.9 billion through Jun 2025, down 9.6%, and an annual FY2023 reading of $4.0 billion, up 4.47% over the prior year.
  • Other Non-Current Liabilities was $3.9 billion for Q2 2025 at Teva Pharmaceutical Industries, down from $4.0 billion in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $4.4 billion in Q2 2024 and bottomed at $2.2 billion in Q3 2021.
  • Average Other Non-Current Liabilities over 5 years is $3.6 billion, with a median of $4.0 billion recorded in 2023.
  • The sharpest move saw Other Non-Current Liabilities surged 49.22% in 2022, then dropped 9.6% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $2.6 billion in 2021, then soared by 49.22% to $3.8 billion in 2022, then rose by 4.47% to $4.0 billion in 2023, then increased by 8.09% to $4.3 billion in 2024, then decreased by 9.35% to $3.9 billion in 2025.
  • Business Quant data shows Other Non-Current Liabilities for TEVA at $3.9 billion in Q2 2025, $4.0 billion in Q1 2025, and $4.3 billion in Q3 2024.